Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus.

Saved in:

Bibliographic Details
Title:	Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus.
Authors:	Alharbi AS; Department of Pediatrics, Prince Sultan Military Medical City, 12233, Riyadh, Saudi Arabia., Abu-Shraie N; King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, 11426, Riyadh, Saudi Arabia., Al Abdulkarim H; King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, 11426, Riyadh, Saudi Arabia., Alharbi IH; King Fahad Armed Forces Hospital, 23311, Jeddah, Saudi Arabia., Averin A; Avalere Health, Washington, DC, 20005, USA., Law AW; Pfizer Inc., New York, NY, 10001, USA., Mendes D; Pfizer Ltd., Tadworth, Surrey, KT20 7NS, UK., Quinn E; Avalere Health, Washington, DC, 20005, USA., Zayed M; Pfizer Gulf FZ LLC, Atlas Group Management Building, 5th Floor, Dubai Media City, Dubai, United Arab Emirates. Mostafa.Zayed@pfizer.com., Behiry A; Pfizer Scientific Technical Limited Company, 13519, Riyadh, Saudi Arabia., Haridy H; Pfizer Gulf FZ LLC, Atlas Group Management Building, 5th Floor, Dubai Media City, Dubai, United Arab Emirates., Mousa M; Pfizer Scientific Technical Limited Company, 13519, Riyadh, Saudi Arabia.
Source:	Infectious diseases and therapy [Infect Dis Ther] 2026 Jun 17. Date of Electronic Publication: 2026 Jun 17.
Publication Type:	Journal Article
Journal Info:	Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther
Database:	MEDLINE Ultimate

Description
ISSN:	2193-8229
DOI:	10.1007/s40121-026-01386-5